CAPLIPOINT - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.4
| Stock Code | CAPLIPOINT | Market Cap | 15,486 Cr. | Current Price | 2,034 ₹ | High / Low | 2,397 ₹ |
| Stock P/E | 39.0 | Book Value | 270 ₹ | Dividend Yield | 0.30 % | ROCE | 27.0 % |
| ROE | 21.1 % | Face Value | 2.00 ₹ | DMA 50 | 1,807 ₹ | DMA 200 | 1,853 ₹ |
| Chg in FII Hold | -0.43 % | Chg in DII Hold | 0.09 % | PAT Qtr | 110 Cr. | PAT Prev Qtr | 87.3 Cr. |
| RSI | 70.8 | MACD | 85.1 | Volume | 95,665 | Avg Vol 1Wk | 1,64,987 |
| Low price | 1,500 ₹ | High price | 2,397 ₹ | PEG Ratio | 2.01 | Debt to equity | 0.00 |
| 52w Index | 59.5 % | Qtr Profit Var | 26.6 % | EPS | 52.2 ₹ | Industry PE | 30.5 |
📊 Financials: CAPLIPOINT has shown strong performance with quarterly PAT rising from 87.3 Cr. to 110 Cr. (+26.6%). ROE at 21.1% and ROCE at 27% reflect excellent efficiency and profitability. Debt-to-equity is 0.00, highlighting a debt-free balance sheet. EPS of 52.2 ₹ supports earnings strength. Cash flows remain healthy, reinforcing overall financial stability.
💹 Valuation: The stock trades at a P/E of 39.0, above the industry average of 30.5, suggesting premium valuation. P/B ratio is ~7.5 (2034/270), indicating expensive pricing relative to book value. PEG ratio of 2.01 signals growth is priced in. Intrinsic value appears lower than current price, implying limited margin of safety at present levels.
🏢 Business Model: CAPLIPOINT operates in the pharmaceutical sector, focusing on specialty formulations. Its competitive advantage lies in strong R&D, niche product portfolio, and debt-free status. High profitability metrics (ROCE, ROE) underline operational strength and sustainable growth potential.
📈 Entry Zone: With RSI at 70.8 (overbought), MACD positive, and price significantly above DMA 50 and 200, the stock looks overheated. A better entry zone would be around 1,800–1,900 ₹ for long-term investors. Holding is justified given strong fundamentals, but caution is advised due to stretched valuations.
Positive
- 📌 Strong ROCE of 27% and ROE of 21.1% indicate excellent efficiency.
- 📌 Debt-free balance sheet (Debt-to-equity 0.00).
- 📌 PAT growth of 26.6% quarter-on-quarter shows momentum.
- 📌 EPS of 52.2 ₹ supports earnings visibility.
Limitation
- ⚠️ High P/E of 39.0 compared to industry average of 30.5.
- ⚠️ P/B ratio of ~7.5 indicates expensive valuation.
- ⚠️ PEG ratio of 2.01 suggests growth is already priced in.
- ⚠️ Low dividend yield of 0.30% limits income appeal.
Company Negative News
- ❌ No major negative news reported, but FII holdings declined (-0.43%).
Company Positive News
- ✅ Strong quarterly profit growth and slight increase in DII holdings (+0.09%).
Industry
- 🏦 Pharmaceutical sector benefits from global demand for specialty formulations.
- 🏦 Industry P/E at 30.5 suggests CAPLIPOINT trades at a premium.
Conclusion
🔑 CAPLIPOINT is fundamentally strong with debt-free operations, high ROCE, and consistent profit growth. However, valuations are stretched with high P/E and P/B ratios. Long-term investors may consider entry around 1,800–1,900 ₹ for better risk-reward balance. Current levels look overheated, but the company remains a solid long-term compounder.
For deeper insights, you could explore a peer comparison or a pharma sector outlook to see how CAPLIPOINT stacks up against competitors.